Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. - Maurer, M. J.; Habermann, T. M.; Shi, Q.; Schmitz, N.; Cunningham, D.; Pfreundschuh, M.; Seymour, J. F.; Jaeger, U.; Haioun, C.; Tilly, H.; Ghesquieres, H.; Merli, F.; et al. (Ann Oncol, 2018)